WuXi Biologics launches drug product facility in China for pre-filled syringes
The global contract research, development and manufacturing organization (CRDMO) has established a global manufacturing network of drug product facilities for vial and pre-filled syringes (PFS) in China and Germany. DP5 is the ninth such plant in that network.
Wuxi said the new facility has PFS capacity to 17 million units per year. “The maximum filling speed can reach 400 PFS/min to support 17 million syringes of drug products manufacturing every year.”
The China headquartered player said the increased manufacturing capacity at the site allows it to provide pharma companies with faster and more robust end-to-end drug product services for their innovative products at different scales and stages.
The DP5 facility also features an advanced isolator filling line for continuous and steady filling services, which offers multiple volume delivery options for PFS.
Single-use technology
The plant contains technology to decrease risk of contamination, added the CDMO.
“Compared to a traditional drug product filling line, DP5’s state-of-the-art design and layout, single-use technology and automated equipment, significantly decrease the risk of contamination and maintain aseptic control required in the filling process. This process supports clients’ products scale up to commercial capability and reliably delivers to patients under the highest quality standards.”
Tapping into the PFS trend
Dr Chris Chen, CEO of WuXi Biologics, said pre-filled syringes have emerged as one of the fastest-growing choices for biologics dosage form as companies seek new and more convenient biologics delivery methods.
“The GMP operation of DP5, our first commercial drug product facility for pre-filled syringes, not only demonstrates our commitment to global partners, but also marks an important milestone for WuXi Biologics to become one of the global leaders in drug product CDMO services. We’ll continue to enable our clients to advance innovative biologics towards clinical trials, regulatory approvals, and commercialization to benefit patients worldwide.”
WuXi Biologics has over 10,000 skilled employees in China, the US, Ireland, Germany, and Singapore. As of the end of 2021, it was supporting over 480 integrated client projects, including nine in commercial manufacturing.
